According to a new report Global Cephalosporin Drugs Market, published by KBV research, The Global Cephalosporin Drugs Market size is expected to reach $14.1 billion by 2025, rising at a market growth of 3.34% CAGR during the forecast period.
The Third-Generation Cephalosporin Drugs market dominated the Global Cephalosporin Drugs Market by Generation in 2018, growing at a CAGR of 3.6 % during the forecast period. The Second-Generation Cephalosporin Drugs market is expected to witness a CAGR of 3.2% during (2019 - 2025).
The Injections market dominated the Global Cephalosporin Drugs Market by Route of Administration in 2018, growing at a CAGR of 3.3 % during the forecast period. The Oral Drugs market is expected to witness a CAGR of 3.5% during (2019 - 2025).
The Asia Pacific market dominated the Global Skin Infection Market by Region in 2018, growing at a CAGR of 3.1 % during the forecast period. The Europe market is expected to witness a CAGR of 3.3% during (2019 - 2025). Additionally, The North America market is expected to witness a CAGR of 5.1% during (2019 - 2025).
Full Report: https://www.kbvresearch.com/cephalosporin-drugs-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of ABBOTT Laboratories, Teva Pharmaceuticals Industries Ltd., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, Baxter International, Inc., Bristol-Myers Squibb Company and Novartis AG.
By Generation
By Application
By Route of Administration
By Type
By Geography
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
